# US 2012/0251535 A1 · Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251535 A1
- Document ID: US20120251535A1
- Status: Published application
- Kind: A1
- Application number: 13/524,837
- Filed: 2012-06-15
- Published: 2012-10-04
- Earliest claimed: 1998-08-11
- Inventors: Antonio J. Grillo-López
- Web page: https://patentgrep.com/patent/US20120251535A1

## CPC

- C07K 16/2887: {against CD20}
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 38/2013: {IL-2}
- A61K 38/212: {IFN-alpha}
- A61K 38/217: {IFN-gamma}
- A61K 39/39541: {against normal tissues, cells}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 51/1027: {against receptors, cell-surface antigens or cell-surface determinants}
- A61K 51/1069: {the tumor cell being from blood cells, e.g. the cancer being a myeloma}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C02F 1/003: {using household-type filters for producing potable water, e.g. pitchers, bottles, faucet mounted devices (C02F9/20 takes precedence)}
- C07K 16/3061: {Blood cells}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C02F 2307/02: as part of a bottle
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/77: Internalization into the cell
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C02F: TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE (separation in general B01D; special arrangements on waterborne vessels of installations for treating water, waste water or sewage, e.g. for producing fresh water, B63J; adding materials to water to prevent corrosion C23F; treating radioactively-contaminated liquids G21F9/04; regeneration of reactants for recirculation into processes, see the relevant places for the processes)

## Abstract

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.

## Claims

### Claim 1

A method of extending median time to progression for responders by at least 13 months in patients with relapsed or refractory, low grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma, comprising administering four doses of 375 mg/m2 of rituximab to the patients.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the patients exhibit an overall response rate to the administration of about 48%.

### Claim 3

A method of treating relapsed or refractory, low-grade or follicular non-Hodgkin's lymphoma in a human patient comprising administering to the patient four weekly infusions of rituximab, each at a dose of 375 mg/m2, wherein the initial infusion rate for the first dose is 50 mg/h, with a subsequent infusion rate increase if no toxicity is seen in the patient, and wherein the second, third, and fourth doses are administered at an infusion rate of more than 50 mg/h.

### Claim 4 (depends on 3)

The method of claim 3, wherein the infusion is interrupted if an infusion-related toxicity reaction is seen in the patient.

### Claim 5 (depends on 4)

The method of claim 4, wherein the infusion is resumed once the infusion-related toxicity reaction subsides.
